

SECURITIES AND EXCHANGE COMMISSION

FORM DEFA14A

Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Filing Date: **2009-01-26**
SEC Accession No. **0001193125-09-010651**

([HTML Version](#) on secdatabase.com)

FILER

CELL THERAPEUTICS INC

CIK: **891293** | IRS No.: **911533912** | State of Incorpor.: **WA** | Fiscal Year End: **1231**
Type: **DEFA14A** | Act: **34** | File No.: **001-12465** | Film No.: **09543603**
SIC: **2834** Pharmaceutical preparations

Mailing Address
501 ELLIOTT AVE W
STE 400
SEATTLE WA 98119

Business Address
501 ELLIOTT AVE W
STE 400
SEATTLE WA 98119
2062707100

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

SCHEDULE 14A

**Proxy Statement Pursuant to Section 14(a) of the Securities
Exchange Act of 1934 (Amendment No.)**

Filed by the Registrant

Filed by a Party other than the Registrant

Check the appropriate box:

- Preliminary Proxy Statement
- Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))**
- Definitive Proxy Statement
- Definitive Additional Materials
- Soliciting Material Pursuant to §240.14a-12

Cell Therapeutics, Inc.

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

- No fee required.
- Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

1) Title of each class of securities to which transaction applies:

2) Aggregate number of securities to which transaction applies:

3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):

4) Proposed maximum aggregate value of transaction:

5) Total fee paid:

Fee paid previously with preliminary materials.

Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

1) Amount Previously Paid:

2) Form, Schedule or Registration Statement No.:

3) Filing Party:

4) Date Filed:

On January 24, 2009, Cell Therapeutics, Inc. (the "Company") issued the following press release in connection with its Special Meeting of Shareholders.



501 Elliott Ave. W. #400 T 206.282.7100
Seattle, WA 98119 F 206.284.6206

Cell Therapeutics, Inc. Provides Update on the Special Meeting of Shareholders

January 24, 2009 Seattle—Cell Therapeutics (CTI) (NASDAQ and MTA: CTIC) announced today that the Company will now hold a Special Meeting of Shareholders on February 27, 2009 in lieu of the Special Meeting of Shareholders that was scheduled to take place on February 6, 2009. Shareholders of record at the close of business on February 4, 2009, the record date established by the Board of Directors, will be entitled to vote at the Special Meeting. Updated proxy materials, including an updated accompanying proxy card, will be mailed to investors shortly after the new record date. The new meeting date was established due to administrative reasons at the discretion of the Board of Directors.

Media Contact:

Cell Therapeutics, Inc.

Dan Eramian

T: 206.272.4343

C: 206.854.1200

F: 206.272.4434

E: media@ctiseattle.com

www.celltherapeutics.com/media.htm

Investors Contact:

Cell Therapeutics, Inc.

Ed Bell

T: 206.272.4345

Lindsey Jesch Logan

T: 206.272.4347

F: 206.272.4434

E: invest@ctiseattle.com

www.celltherapeutics.com/investors.htm